Browse GGT5

Summary
SymbolGGT5
Namegamma-glutamyltransferase 5
Aliases GGT-REL; GGTLA1; gamma-glutamyltransferase-like activity 1; GGL; GGT 5; gamma-glutamyl cleaving enzyme; gamm ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Membrane Single-pass type II membrane protein
Domain -
Function

Cleaves the gamma-glutamyl peptide bond of glutathione conjugates, but maybe not glutathione itself. Converts leukotriene C4 (LTC4) to leukotriene D4 (LTD4).

> Gene Ontology
 
Biological Process GO:0006520 cellular amino acid metabolic process
GO:0006575 cellular modified amino acid metabolic process
GO:0006631 fatty acid metabolic process
GO:0006633 fatty acid biosynthetic process
GO:0006636 unsaturated fatty acid biosynthetic process
GO:0006690 icosanoid metabolic process
GO:0006691 leukotriene metabolic process
GO:0006749 glutathione metabolic process
GO:0006750 glutathione biosynthetic process
GO:0006790 sulfur compound metabolic process
GO:0016053 organic acid biosynthetic process
GO:0019184 nonribosomal peptide biosynthetic process
GO:0019370 leukotriene biosynthetic process
GO:0033559 unsaturated fatty acid metabolic process
GO:0042398 cellular modified amino acid biosynthetic process
GO:0044272 sulfur compound biosynthetic process
GO:0044283 small molecule biosynthetic process
GO:0046394 carboxylic acid biosynthetic process
GO:0046456 icosanoid biosynthetic process
GO:0072330 monocarboxylic acid biosynthetic process
Molecular Function GO:0003840 gamma-glutamyltransferase activity
GO:0008238 exopeptidase activity
GO:0008242 omega peptidase activity
GO:0016746 transferase activity, transferring acyl groups
GO:0016755 transferase activity, transferring amino-acyl groups
GO:0036374 glutathione hydrolase activity
Cellular Component GO:0009897 external side of plasma membrane
GO:0031225 anchored component of membrane
GO:0031233 intrinsic component of external side of plasma membrane
GO:0031362 anchored component of external side of plasma membrane
GO:0046658 anchored component of plasma membrane
GO:0098552 side of membrane
> KEGG and Reactome Pathway
 
KEGG hsa00430 Taurine and hypotaurine metabolism
hsa00480 Glutathione metabolism
hsa00590 Arachidonic acid metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-5423646: Aflatoxin activation and detoxification
R-HSA-2142753: Arachidonic acid metabolism
R-HSA-211859: Biological oxidations
R-HSA-156590: Glutathione conjugation
R-HSA-174403: Glutathione synthesis and recycling
R-HSA-1430728: Metabolism
R-HSA-556833: Metabolism of lipids and lipoproteins
R-HSA-156580: Phase II conjugation
R-HSA-2142691: Synthesis of Leukotrienes (LT) and Eoxins (EX)
Summary
SymbolGGT5
Namegamma-glutamyltransferase 5
Aliases GGT-REL; GGTLA1; gamma-glutamyltransferase-like activity 1; GGL; GGT 5; gamma-glutamyl cleaving enzyme; gamm ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between GGT5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolGGT5
Namegamma-glutamyltransferase 5
Aliases GGT-REL; GGTLA1; gamma-glutamyltransferase-like activity 1; GGL; GGT 5; gamma-glutamyl cleaving enzyme; gamm ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of GGT5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolGGT5
Namegamma-glutamyltransferase 5
Aliases GGT-REL; GGTLA1; gamma-glutamyltransferase-like activity 1; GGL; GGT 5; gamma-glutamyl cleaving enzyme; gamm ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of GGT5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.7570.0648
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.880.601
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.6570.553
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.3170.504
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.7410.694
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.2240.93
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.330.542
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.5830.567
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-0.1140.929
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.8440.618
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.9610.394
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.6260.000446
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of GGT5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13117.707.71
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38275.33.71.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.57.15.41
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11139.109.10.458
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 6116.7016.71
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolGGT5
Namegamma-glutamyltransferase 5
Aliases GGT-REL; GGTLA1; gamma-glutamyltransferase-like activity 1; GGL; GGT 5; gamma-glutamyl cleaving enzyme; gamm ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of GGT5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolGGT5
Namegamma-glutamyltransferase 5
Aliases GGT-REL; GGTLA1; gamma-glutamyltransferase-like activity 1; GGL; GGT 5; gamma-glutamyl cleaving enzyme; gamm ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of GGT5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by GGT5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolGGT5
Namegamma-glutamyltransferase 5
Aliases GGT-REL; GGTLA1; gamma-glutamyltransferase-like activity 1; GGL; GGT 5; gamma-glutamyl cleaving enzyme; gamm ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of GGT5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolGGT5
Namegamma-glutamyltransferase 5
Aliases GGT-REL; GGTLA1; gamma-glutamyltransferase-like activity 1; GGL; GGT 5; gamma-glutamyl cleaving enzyme; gamm ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of GGT5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolGGT5
Namegamma-glutamyltransferase 5
Aliases GGT-REL; GGTLA1; gamma-glutamyltransferase-like activity 1; GGL; GGT 5; gamma-glutamyl cleaving enzyme; gamm ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between GGT5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolGGT5
Namegamma-glutamyltransferase 5
Aliases GGT-REL; GGTLA1; gamma-glutamyltransferase-like activity 1; GGL; GGT 5; gamma-glutamyl cleaving enzyme; gamm ......
Chromosomal Location22q11.23
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting GGT5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.